Pharmaceutical company K.N.A. Inter Pharma joins forces with Diamond Biotechnology in an ambitious plan to transform Thailand into a leading global center for medical device manufacturing within the beauty industry.
In a significant move for Thailand's beauty industry, K.N.A. Inter Pharma Co., Ltd. and Diamond Biotechnology Co., Ltd. have formed a strategic partnership to establish the country's first medical device manufacturing plant for aesthetic medicine. The joint venture, located in Pathum Thani Province, is set to elevate Thailand's beauty industry to a global level and position it as a fully integrated "Medical Hub."
The partnership, with a total investment exceeding THB 2.5 billion, aims to produce innovative medical devices focused on aesthetic treatments. The collaboration leverages Diamond Biotechnology's expertise as a global leader in biomedical and aesthetic medical products, with headquarters in Taiwan, and includes support from prominent Thai medical professionals and clinic founders.
The new facility, scheduled to begin construction on January 1, 2026, and expected to commence production in 2027, will initially produce four patented aesthetic medical devices. The company plans to distribute these products throughout regional Southeast Asian markets, eventually expanding to markets in China and the Middle East.
Dr. Aaron Shia-Hsien Hsia, Chairman of Diamond Biotechnology Co., Ltd., expressed confidence in Thailand's potential as the region's Medical Hub. K.N.A., on the other hand, recognizes Diamond Biotechnology as a pioneer in cutting-edge biomedical technologies and sees this partnership as an opportunity to bring manufacturing know-how and expertise to Thailand.
The joint venture has a registered capital of THB 500 million specifically for the plant's setup. An additional budget worth over THB 2 billion has been allocated for infrastructure, machinery, R&D, and the four patented aesthetic medical instrument products.
Notable medical partners supporting the project include Dr. Piyawat Hirunnard M.D., Dr. Nataya Rakpuang M.D., and Dr. Kittitad Sinpipatporn M.D., as well as Dr. Rassapoom Sumaetheiwit, M.D., Dermatologist and Founder of Rassapoom Clinic, who will serve as an advisor in product development tailored to aesthetic medical needs.
The partnership reflects K.N.A.'s vision of becoming a comprehensive aesthetic innovation leader, according to Mr. Nadrincha Patan, President of K.N.A. Inter Pharma Co., Ltd. By selecting Thailand as their sole production base in Asia, Diamond Biotechnology aims to serve the entire Asian and Middle Eastern markets.
The collaboration is expected to enhance treatment standards, boost consumer confidence, reduce import dependency, lower costs, create jobs, and generate national income in Thailand. It is a significant step towards Thailand's goal of becoming a global leader in the aesthetic medicine industry.
- This strategic partnership between K.N.A. Inter Pharma Co., Ltd. and Diamond Biotechnology Co., Ltd. intends to establish Thailand's first medical device manufacturing plant for aesthetic medicine, positioning the country as a fully integrated "Medical Hub" on an international scale.
- The joint venture, with a total investment exceeding THB 2.5 billion, focuses on producing innovative medical devices with a concentration on aesthetic treatments.
- The collaboration leverages Diamond Biotechnology's expertise as a global leader in biomedical and aesthetic medical products, and includes support from prominent Thai medical professionals and clinic founders.
- The new facility, scheduled to begin construction in 2026, will initially produce four patented aesthetic medical devices, aiming to distribute these products throughout regional Southeast Asian markets and eventually expanding to markets in China and the Middle East.
- The partnership reflects K.N.A.'s vision of becoming a comprehensive aesthetic innovation leader, while Diamond Biotechnology serves the entire Asian and Middle Eastern markets by selecting Thailand as their sole production base in Asia.
- The collaboration is expected to enhance treatment standards, boost consumer confidence, reduce import dependency, lower costs, create jobs, and generate national income in Thailand – moving the country closer to its goal of becoming a global leader in the aesthetic medicine industry.
- The partnership in the beauty industry, involving technological innovation and business expansion, is a significant investment not only in the health and wellness sector but also in the broader realm of Thailand's finance, lifestyle, fashion and beauty, and science industries.
